Status:
COMPLETED
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Neovascular (Wet) Age-related Macular Degeneration
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local pro...
Detailed Description
The prospective observation period per patient will be up to 24 months. A minimum of one follow-up visit per year is required in order to maintain patient's participation in the study. The baseline v...
Eligibility Criteria
Inclusion
- Male or female patients, ≥18 years of age, being treated with Lucentis® for any approved indication in the local Lucentis® SmPC
- Written informed consent
Exclusion
- As described in Lucentis® SmPC
- Participation in any other clinical study or NIS with Lucentis® as the investigational drug (such as OCEAN or LUMINOUS)
Key Trial Info
Start Date :
June 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
5500 Patients enrolled
Trial Details
Trial ID
NCT04847895
Start Date
June 1 2015
End Date
March 31 2021
Last Update
April 19 2021
Active Locations (175)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Ettlingen, Baden-Wurttemberg, Germany, 76275
2
Novartis Investigative Site
Ahaus, Germany, 48683
3
Novartis Investigative Site
Andernach, Germany, 56626
4
Novartis Investigative Site
Augsburg, Germany, 86150